A Phase 2 interventional study of Vortioxetine in Fronto-temporal Dementia, Fronto-temporal Lobar Dementia and Frontotemporal Degeneration, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-09.
Sponsored by Johns Hopkins University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Frontotemporal Dementia with a site in United States — 31 open to participants now, 45 under way, none of them phase 3. Frontotemporal Dementia · United States.
Among the 103 studies in Frontotemporal Dementia with a site in United States, this one is the 36th largest by planned enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2025, is one of 14 in phase 2, reaches primary completion later than 29 of the 44 other live ones, and was the 93rd registered.
208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.
Browse Frontotemporal Dementia studies →31 of the 103 studies in Frontotemporal Dementia with a site in United States are open now. Recruiting first, the newest first:
Institute for Molecular Medicine · Sites in United States
Ages 65–80
Maya Henry · Sites in United States
Ages 40+
Oregon Health and Science University · Sites in United States
Ages 18–100 · Healthy volunteers
University of Chicago · Sites in United States
Ages 18–100
University of Pennsylvania · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 51 Frontotemporal Dementia studies recruiting now, 29 (57%) set no upper age limit and 5 (10%) stop at 75 or younger; 6 take children under 18; 30 take healthy volunteers.
This study: 45 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 19 · Phase 3 5 · Phase 4 3
First in 2001; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is close to the median of 50 across 128 interventional studies indexed under Frontotemporal Dementia.
Median enrollment 60 across the 66 interventional studies, 201 across the 37 observational. Of the 52 that completed or were terminated, 17 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 103 have an industry lead sponsor. The 10 most frequent:
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
Johns Hopkins University has 4 studies filed under Frontotemporal Dementia — fewer than ten, so there is no comparison to draw.
14 of the studies in Frontotemporal Dementia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05262023Denali Therapeutics Inc.A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) | 2026-12 |
| NCT03233646Duke UniversityRetinal Imaging in Neurodegenerative Disease | 2026-12-31 |
| NCT03702907Georgetown UniversityDC Longitudinal Study on Aging and Specimen Bank | 2027-01 |
| NCT05184569Peter Ljubenkov, MDVeri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology | 2027-01-31 |
| NCT04516499The Bluefield Project to Cure Frontotemporal DementiaNeurofilament Surveillance Project (NSP) | 2027-02 |
Add all 14 to your calendar (.ics) → With an account.
Among the 103 studies in Frontotemporal Dementia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if vortioxetine improves mood symptoms and cognition in patients with early-stage behavioral variant Frontotemporal Dementia (bvFTD). The main questions this study aims to answer are:
Researchers will also determine whether there are changes in the brain associated with vortioxetine treatment.
Participants will:
FTD Patients
Inclusion Criteria:
Exclusion Criteria:
Healthy Controls
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals with bvFTD and mood symptoms receiving the study drug, vortioxetine.
Drug: Vortioxetine
Individuals with bvFTD and mood symptoms will receive approximately 12 weeks of treatment with vortioxetine
Also known as: Trintellix
Change in global cerebral glucose metabolism on [18F] fluorodeoxyglucose Positron Emission Tomography (FDG PET)
Cerebral glucose uptake measured through 18F FDG positron emission tomography
Time frame: Baseline, 12 weeks
Change in depressive symptoms as assessed by the Hamilton Depression Rating Scale (HDRS).
The HDRS is a widely used clinician-administered depression assessment tool designed to measure the severity of depression in individuals. It consists of 17 items rated on a 3 or 5 point scale with total scores ranging from 0 to 52. A higher score indicates more severe symptoms of depression.
Time frame: Baseline, 12 weeks
Change in performance on the Trail Making Test (TST).
The TMT is a widely used neuropsychological test that assesses an individuals cognitive abilities including executive function, attention, processing speed, and mental flexibility. It is divided into two parts: Trail Making Test A and Trail Making Test B. The Trail Making Test A primarily assesses visual attention and processing speed. Time taken to complete the task is recorded, with faster times indicating better cognitive performance. The Trail Making Test B primarily assesses cognitive flexibility, executive functioning, task switching and attention. Time taken to complete the task is recorded, with faster times indicating better cognitive performance.
Time frame: Baseline, 12 weeks
Plan to share: Yes — All de-identified data will be preserved and shared in the National Archive of Computerized Data on Aging (NACDA).
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Data will shared 12 months after study starts and every 6 months thereafter. All data will be shared upon publication or at the end of the award period, whichever is sooner. For published studies, data will be shared when the pre- print is available. NACDA studies have digital object identifiers (DOI) to aid in findability. The investigators will include that DOI in relevant publications. NACDA will make decisions about how long to preserve the data, but that data archive has not deleted any deposited data up to now.
Access criteria: Given that all data will be de-identified, the investigators do not plan to control access to the data or require a Data Use Agreement. Data submitted to NACDA that are evaluated as constituting a low disclosure risk are publicly released and available to download directly from the NACDA website. The investigators plan to prepare and submit the data in a de-identified format in order to minimize any disclosure risk and allow for public release through NACDA. NACDA performs an evaluation of all submitted data prior to release to ensure disclosure risks are minimized, and the investigators anticipate approval for public release of data without restriction through the NACDA website.
Data sharing details ↗ · www.icpsr.umich.edu
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for May 2029, 50 months after the start.
Of 19 phase 2 interventional studies under Frontotemporal Dementia, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 64. This study's planned 50 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine